APLS vs SBAC · rev $1.00B vs P/E 30, rev $1.42B
Apellis Pharmaceuticals Inc (APLS) versus SBA Communications Corp (SBAC) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
SBA Communications Corp (SBAC) is a reit - specialty company listed on US.
Latest reported APLS revenue for 2025-12-31 was $1.00B. Net income was $22.4M. Revenue was up 28.5% from 2024-12-31 to 2025-12-31. APLS currently screens at market cap $2.29B.
Latest reported SBAC revenue for 2026-06-30 was $1.42B. Net income was $383.6M. SBAC currently screens at market cap $24.58B and trailing P/E 30.3.
APLS currently screens at market cap $2.29B. SBAC currently screens at market cap $24.58B and trailing P/E 30.3.
Not investment advice. Open the APLS and SBAC stock pages for the full models.
Not investment advice.